
News|Articles|February 13, 2019
Elzonris for Blastic Plasmacytoid Dendritic Cell Neoplasm
Author(s)Drew Boxler
Advertisement
ELZONRIS (tagraxofusp-erzs, Stemline® Therapeutics)
Indications: Treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older
Dosage: Intravenously at 2mcg/kg over 15 mins once daily on days 1 & 5 of a 21-day cycle
- First cycle recommended in inpatient setting, subsequent cycles either inpatient or other appropriate outpatient setting
Contraindications: None
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
How Pharmacists Take Control of Medical Billing
2
Data Show Rise in GLP-1 Poison Center Calls Tied to Dosing Errors
3
Lowered Pneumococcal Vaccination Age Has Yet to Close Awareness Gap
4
FDA Approves First Oral PCSK9 Inhibitor to Lower LDL Cholesterol
5






























